# A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects

> **NCT03239353** · PHASE1 · COMPLETED · sponsor: **Aucta Pharmaceuticals, Inc** · enrollment: 40 (actual)

## Conditions studied

- HBV

## Interventions

- **DRUG:** Entecavir

## Key facts

- **NCT ID:** NCT03239353
- **Lead sponsor:** Aucta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-20
- **Primary completion:** 2018-05-29
- **Final completion:** 2018-06-20
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03239353

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03239353, "A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Entecavir Extended Release (XR) in Healthy Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03239353. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*